Saturday 17 October 2026
Export DRTS’s income statement to Excel — free account
Alpha Tau Medical Ltd.
DRTS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 100.0%, free cash flow fell 30.4% and total debt rose 12.8%, each against the same quarter a year earlier.
12.29
0.87
−6.61%
Follow DRTS
Alpha Tau Medical Ltd. (DRTS) P/E ratio
Alpha Tau Medical Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LBRX LB Pharmaceuticals Inc compare | n/m |
| GHRS GH Research PLC compare | n/m |
| DMRA Galecto, Inc. compare | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| NKTR Nektar Therapeutics compare | n/m |
| DRTS Alpha Tau Medical Ltd. | n/m |
| TSHA Taysha Gene Therapies, Inc. compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)